Sentences with phrase «increasing number of clinical trials»

Although these platforms can be used successfully for small - scale expansion of hMSCs, other platforms will be required to generate the quantity of cells required to support the increasing number of clinical trials utilizing hMSCs and the subsequent large - scale production.

Not exact matches

And it doesn't really do what it's supposed to: When Sprout conducted clinical trials, women only reported a small increase in the number of times they had satisfying sex — around one additional time per month.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Data from the clinical trial did show that the combination therapy substantially decreased the number of pulmonary exacerbations and hospitalizations, while also beneficially increasing the weight of CF patients.

Following a number of successful clinical trials the use of use of baclofen increased massively and sales of the drug have soared in some countries.

Preserving livers at body temperature may improve transplant outcomes and increase viable donor liver numbers, according to the results of a new UK clinical trial.

The objective of the fellowship is to provide an in - depth clinical research training experience at a premier medical center with expertise and significant clinical volume in the area of biochemical genetics, including lysosomal storage diseases, as well as in therapeutics and clinical trials involving patients with these and other metabolic diseases and, thereby, to increase the number of medical geneticists with interest, knowledge, and expertise in this area.

It aims to increase the number of successful new treatments for cancer by taking undeveloped anti-cancer agents from industry and putting them into clinical trials.

Increasing number of manufacturers are developing new medications for the treatment of TBI and large number of clinical trials are conducted in order to better understand the etiology of the condition.»

We stratified randomisation by site and maintained balance between groups within each stratum using a minimisation method using computer - generated random numbers to give an equal chance of allocation to each group when groups within the stratum were balanced and an increased chance (0.667) of allocation to the smaller group when there was an imbalance within the stratum.69 The randomisation service at Warwick Clinical Trials Unit generated the random allocation sequence and informed the FLNP co-ordinators of group allocation following recruitment of a family by the researchers.